<DOC>
	<DOC>NCT01567813</DOC>
	<brief_summary>This is a post-licensure safety observation cohort study to describe the general safety of GARDASIL™ (a quadrivalent human papillomavirus vaccine) in males.</brief_summary>
	<brief_title>Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Inclusion criteria: Male vaccinated with at least one dose of GARDASIL™ after the October 2009 FDA date of first licensure of GARDASIL™ for males Exclusion criteria all cohorts: Female Male vaccinated prior to the October 2009 FDA date of first licensure of GARDASIL™ for males Male who received all doses of GARDASIL™ outside of the health plan Exclusion criteria, Regimen Completers cohort: Male &lt; 9 and &gt; 26 years of age at first dose Male not part of health plan at each dose 3dose vaccination regimen given over a period &gt; 12 months Less than 28day interval between first and second dose Less than 12 weeks between the second and third dose Less than 24 weeks between first and third dose Exclusion criteria, Autoimmune cohort: Male with less than 12 months of health plan membership prior to first dose of GARDASIL™</criteria>
	<gender>Male</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Warts</keyword>
	<keyword>Papillomavirus infections</keyword>
	<keyword>DNA virus infections</keyword>
	<keyword>Virus diseases</keyword>
	<keyword>Skin diseases, viral</keyword>
	<keyword>Tumor virus infections</keyword>
	<keyword>Skin diseases, infectious</keyword>
	<keyword>Skin diseases</keyword>
</DOC>